Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Income from Continuing Operations
Aquestive Therapeutics Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Income from Continuing Operations
-$28.8m
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Aquestive Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-28.8m
USD
Based on the financial report for Mar 31, 2024, Aquestive Therapeutics Inc's Income from Continuing Operations amounts to -28.8m USD.
What is Aquestive Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
19%
Over the last year, the Income from Continuing Operations growth was 13%. The average annual Income from Continuing Operations growth rates for Aquestive Therapeutics Inc have been 19% over the past three years , 19% over the past five years .